KeyBanc analyst Paul Knight upgraded Avid Bioservices to Overweight from Sector Weight with a $20 price target. The company pointed to a robust biological contract manufacturing environment and exceeded estimates with its Q3 results, the analyst tells investors in a research note. The firm cites robust industry demand, a building backlog, and the company’s operating leverage for the upgrade.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CDMO:
- Avid Bioservices reports Q3 EPS 1c, consensus (3c)
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2023, and Recent Developments
- Avid Bioservices says no cash held at Silicon Valley Bank
- Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2023 After Market Close on March 13, 2023
